Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Ascendis Pharma (ASND) to $256 from $250 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma: Strong Yorvipath Momentum, Pipeline Upside, and Raised DCF Assumptions Underpin Buy Rating and $260 Target
- Ascendis Pharma: Accelerating Commercial Momentum and Pipeline Execution Support Higher Target and Buy Rating
- ASND: Strong Yorvipath Momentum and Pipeline Catalysts Underpin Buy Rating and Long‑Term Upside
- Ascendis Pharma Posts Strong 2025 Results as YORVIPATH Drives Growth and TransCon Pipeline Advances
- Ascendis Pharma reports Q4 EPS (EUR 0.55) vs. (EUR 0.64) last year